Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot randomized trial of intravenous-only versus standard therapy for melioidosis
ACTRN12622000225718Phase 4Terminated
- Sponsor
- Cairns Hospital
- Start
- Apr 2022
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of meropenem, ceftazidime and trimethoprim + sulfamethoxazole in melioidosis (2 arms), sponsored by Cairns Hospital. Primary endpoint: Culture-confirmed recrudescence or relapse of melioidosis. Started Apr 2022; status: terminated.
02
Drugs
meropenemceftazidimetrimethoprim + sulfamethoxazole
03
Conditions
melioidosis
Beyond the preview
Go deeper on ACTRN12622000225718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000225718.